Modulight

Selskabet har haft et bedre år i 2025. Visibiliteten for fremtiden er dog begrænset.

14:40

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Modulight's revenue grew significantly, and its losses narrowed from a weak comparison period.

Modulight will publish its Q3 results on Friday, October 24 at 1:00 pm EEST.

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

The outcome of the negotiations was clearly milder than expected, and redundancies will be avoided entirely.

We continue our series of articles focusing on Life Science investing, the first four parts of which focused on drug development. Subsequent articles will cover medical devices.

Modulight announced on Thursday that it would start change negotiations. The negotiations, which are being initiated for financial and production-related reasons, aim to streamline operations and improve profitability.

Modulight’s revenue grew by triple-digit percentages, its operating loss was cut in half, and our estimates were exceeded. The company reported brisk trading during the summer, and revenue was also supported by the partial recognition of the quantum computing order.

Earlier this year, the company reported an increase in the order book and the number of hospitals using its products. Based on this message, we expect growing revenue for the quarter.